Akari Therapeutics Targets Mid-2027 Human Trial for Urothelial Cancer ADC Candidate AKTX-101

Akari Therapeutics disclosed preclinical data supporting AKTX-101, its antibody-drug conjugate candidate for urothelial cancer, and set a mid-2027 target for its first human trial. The company framed the data as evidence of a differentiated ADC strategy relative to existing approaches in the space, positioning AKTX-101 as distinct in its mechanism or targeting profile. The preclinical readout builds momentum ahead of the IND-enabling work required to reach the clinic, with the mid-2027 human trial timeline serving as the next key milestone investors will watch.